Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00730_DB00969_nanopub.RA1JL9Or0SugYe9IbpFpV24zFepIUCq-w5GmZnV9ulK7c#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00730_DB00969 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00730_DB00969 label "DDI between Thiabendazole and Alosetron - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed. [drugbank_resource:DB00730_DB00969]" assertion.
- drugbank_resource:DB00730_DB00969 identifier "drugbank_resource:DB00730_DB00969" assertion.
- drugbank_resource:DB00730_DB00969 title "DDI between Thiabendazole and Alosetron - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB00730 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00730_DB00969 assertion.
- drugbank:DB00969 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00730_DB00969 assertion.